Mind Medicine (MindMed) Inc. (MNMD)

USD 7.23

(-3.41%)

Market Cap (In USD)

529.82 Million

Revenue (In USD)

-

Net Income (In USD)

-95.73 Million

Avg. Volume

1.09 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.37-12.22
PE
-
EPS
-
Beta Value
2.332
ISIN
CA60255C8850
CUSIP
60255C109
CIK
1813814
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert Barrow
Employee Count
-
Website
https://www.mindmed.co
Ipo Date
2016-11-15
Details
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.